Daily Roundup

GNP.ASX LPE.ASX KCN.ASX EMV.ASX SPL.ASX

GenusPlus Lands $55 Million Rio Tinto Contract

GenusPlus Group Ltd has secured a significant $55 million contract from Rio Tinto to construct a 220kV Millstream Substation expansion in Western Australia's Pilbara region. Work kicks off immediately, with completion targeted for mid-2028. The project, located roughly 80 kilometres south of Karratha, will employ around 50 personnel and represents a major boost to GenusPlus' order book while deepening its partnership with the mining giant.

Locality Planning Energy Halts Trading Ahead of Major Announcement

Locality Planning Energy Holdings Limited has requested a voluntary suspension from quotation effective immediately, pending the release of a material contract announcement. The suspension will remain in place until the company makes its announcement or trading resumes on Thursday, 16 July 2026. The move signals that shareholders should expect significant news in the coming hours.

Kingsgate Restores Gold Mine Processing Capacity

Kingsgate Consolidated has made solid progress on remediation works at its Chatree Gold Mine's Plant 1. The facility has successfully restarted with a modified circuit configuration, restoring approximately 50% of normal processing capacity—equivalent to roughly 130 wet tonnes per hour. The SAG Mill 1 is now running in closed-circuit mode while the Ball Mill undergoes repairs, with replacement lubrication components already in procurement. Mining operations continue uninterrupted throughout the remediation period.

EMVision Advances Clinical Programs with Strong Cash Position

EMVision Medical Devices has reported solid progress on its neurodiagnostic technology platform. The company surpassed key enrolment milestones in its Pivotal Validation Trial and successfully completed a First Responder aeromedical feasibility study. EMVision also secured $2.0 million in grant funding and maintains a robust balance sheet with $17.1 million in cash reserves, plus another $4.6 million in non-dilutive funding available under current grant programs. The company is now preparing to add an acute ischaemia detection endpoint to strengthen its clinical value proposition.

Starpharma Advances Oncology Pipeline and Secures Funding

Starpharma Holdings has completed the preclinical data package for its DEP® HER2-Lu radiopharmaceutical and begun manufacturing dendrimer components under GMP standards, paving the way for a Phase 1 clinical study in the second half of 2026. The biotech firm also filed a new patent application covering DEP® technology in radioligand therapy and achieved a milestone under its Radiopharm Theranostics collaboration, triggering a $0.5 million option fee. The company generated strong interest at the BIO International Convention, with customer receipts jumping 149% year-on-year.

To fuel its growth, Starpharma announced a fully underwritten entitlement offer raising $32 million at $0.57 per share—a 25% discount to the last closing price. The capital raise will extend the company's cash runway into FY28 and support ongoing oncology development. Eligible shareholders can participate on a one-for-7.5 pro rata basis, with the offer price representing a 22% discount to the theoretical ex-rights price of $0.73.